... Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium.
News
- Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ...
- Spectrum Pharmaceuticals Announces Results from the RECOVER Phase 3 Study of ROLONTIS ...
... from the Phase 3 RECOVER clinical study was presented during the 2018 San Antonio Breast Cancer Symposium ® (SABCS). ... Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, ...
- Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 ...
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of ... HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio ...
- Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of ...
... drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that .... NERLYNX is a registered trademark of Puma Biotechnology, Inc.
- Puma Biotech (PBYI) Announces Results from Phase II SUMMIT Trial of Neratinib for ERBB2 ...
Puma Biotech (PBYI) Announces Results from Phase II SUMMIT Trial of ... Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, ... at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently ...